Ost-müük Phathom Pharmaceuticals, Inc. - PHAT CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Kauplemistingimused
| Hinnavahe | 0.08 | ||||||||
|
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.025457% | ||||||||
|
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.003235% | ||||||||
| Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
| Min kauplemise kogus | 1 | ||||||||
| Valuuta | USD | ||||||||
| Tagatis | 20% | ||||||||
| Aktsiabörs | United States of America | ||||||||
| Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Phathom Pharmaceuticals Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Võtmestatistika
| Eelmine sulgemine* | 11.68 |
| Avatud* | 11.58 |
| Aastane muutus* | 57.77% |
| Päeva ulatus* | 11.58 - 11.86 |
| 52 nädala ulatus | 5.84-14.45 |
| Keskmine maht (10 päeva) | 547.18K |
| Keskmine maht (3 kuud) | 9.22M |
| Turukapitalisatsioon | 643.23M |
| P/E suhtarv | -100.00K |
| Ringluses olevad aktsiad | 43.61M |
| Tulu | N/A |
| EPS | -4.87 |
| Dividendid (% kasumist) | N/A |
| Beeta | 0.36 |
| Järgmine tuluaruande kuupäev | Jul 31, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
|---|---|---|---|---|---|---|
| May 26, 2023 | 11.74 | 0.11 | 0.95% | 11.63 | 11.92 | 11.55 |
| May 25, 2023 | 11.68 | -0.03 | -0.26% | 11.71 | 11.78 | 11.36 |
| May 24, 2023 | 11.67 | -0.26 | -2.18% | 11.93 | 12.02 | 11.37 |
| May 23, 2023 | 13.02 | 0.20 | 1.56% | 12.82 | 13.75 | 12.82 |
| May 22, 2023 | 13.42 | 0.60 | 4.68% | 12.82 | 13.59 | 12.78 |
| May 19, 2023 | 13.19 | 0.21 | 1.62% | 12.98 | 13.32 | 12.82 |
| May 18, 2023 | 12.90 | -0.07 | -0.54% | 12.97 | 13.29 | 12.50 |
| May 17, 2023 | 13.23 | 1.20 | 9.98% | 12.03 | 13.36 | 12.03 |
| May 16, 2023 | 12.47 | 0.20 | 1.63% | 12.27 | 12.66 | 12.01 |
| May 15, 2023 | 12.55 | -0.77 | -5.78% | 13.32 | 13.58 | 12.48 |
| May 12, 2023 | 13.42 | 0.45 | 3.47% | 12.97 | 14.16 | 12.97 |
| May 11, 2023 | 13.14 | 0.26 | 2.02% | 12.88 | 14.33 | 12.85 |
| May 10, 2023 | 12.38 | 0.40 | 3.34% | 11.98 | 12.61 | 11.18 |
| May 9, 2023 | 11.95 | -0.31 | -2.53% | 12.26 | 12.34 | 11.74 |
| May 8, 2023 | 12.27 | -0.06 | -0.49% | 12.33 | 13.06 | 12.01 |
| May 5, 2023 | 12.30 | 0.54 | 4.59% | 11.76 | 12.49 | 11.64 |
| May 4, 2023 | 11.66 | 0.18 | 1.57% | 11.48 | 11.92 | 11.21 |
| May 3, 2023 | 11.57 | 0.59 | 5.37% | 10.98 | 11.84 | 10.93 |
| May 2, 2023 | 10.95 | -0.10 | -0.90% | 11.05 | 11.34 | 10.57 |
| May 1, 2023 | 11.04 | 0.39 | 3.66% | 10.65 | 11.44 | 10.52 |
Phathom Pharmaceuticals, Inc. Events
| Kellaaeg (UTC) (UTC) | Riik | Sündmus |
|---|---|---|
| Wednesday, June 7, 2023 | ||
| Kellaaeg (UTC) (UTC) 17:30 | Riik US
| Sündmus Phathom Pharmaceuticals Inc at Jefferies Healthcare Conference Phathom Pharmaceuticals Inc at Jefferies Healthcare ConferenceForecast -Previous - |
| Wednesday, June 14, 2023 | ||
| Kellaaeg (UTC) (UTC) 15:00 | Riik US
| Sündmus Phathom Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Phathom Pharmaceuticals Inc at Goldman Sachs Healthcare ConferenceForecast -Previous - |
| Monday, July 31, 2023 | ||
| Kellaaeg (UTC) (UTC) 12:00 | Riik US
| Sündmus Q2 2023 Phathom Pharmaceuticals Inc Earnings Release Q2 2023 Phathom Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
| Monday, November 6, 2023 | ||
| Kellaaeg (UTC) (UTC) 10:59 | Riik US
| Sündmus Q3 2023 Phathom Pharmaceuticals Inc Earnings Release Q3 2023 Phathom Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Kogutulu | 0 | 0 | 0 | 0 | 0 |
| Kogu tegevuskulu | 172.44 | 137.08 | 125.665 | 106.215 | 1.225 |
| Müük/Üldine/admin kulud, kokku | 100.999 | 62.742 | 27.517 | 6.944 | 1.205 |
| Uuringud ja arendus | 71.441 | 72.338 | 98.148 | 99.271 | 0.02 |
| Tulud majandustegevusest | -172.44 | -137.08 | -125.665 | -106.215 | -1.225 |
| Intressitulud (kulu), muud tulud, neto | -25.173 | -6.747 | -3.49 | -3.088 | -0.013 |
| Muud, neto | -0.11 | -0.056 | 0.087 | -145.828 | -0.05 |
| Netotulu enne makse | -197.723 | -143.883 | -129.068 | -255.131 | -1.288 |
| Netotulu pärast makse | -197.723 | -143.883 | -129.068 | -255.131 | -1.288 |
| Netotulu enne erikulusid | -197.723 | -143.883 | -129.068 | -255.131 | -1.288 |
| Netotulu | -197.723 | -143.883 | -129.068 | -255.131 | -1.288 |
| Arvestatav tulu, v a erikulud | -197.723 | -143.883 | -129.068 | -255.131 | -1.288 |
| Arvestatav tulu, koos erikuludega | -197.723 | -143.883 | -129.068 | -255.131 | -1.288 |
| Jaotamisele kuuluv netotulu | -197.723 | -143.883 | -129.068 | -255.131 | -1.288 |
| Keskmine jaotamisele kuuluv aktsia kohta | 39.1182 | 30.5112 | 33.2282 | 24.7283 | 25.8835 |
| Jaotatav EPS, v a erakorralised kulud | -5.0545 | -4.71574 | -3.8843 | -10.3174 | -0.04976 |
| Dividends per Share - Common Stock Primary Issue | 0 | ||||
| Jaotamisele kuuluv normaal-EPS | -5.0545 | -4.65019 | -3.8843 | -10.3174 | -0.04976 |
| Ootamatud kulutused (tulu) | 2 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Kogutulu | 0 | 0 | 0 | 0 | 0 |
| Kogu tegevuskulu | 30.077 | 46.642 | 42.529 | 45.363 | 37.906 |
| Müük/Üldine/admin kulud, kokku | 18.598 | 30.696 | 23.509 | 26.548 | 20.246 |
| Uuringud ja arendus | 11.479 | 15.946 | 19.02 | 18.815 | 17.66 |
| Tulud majandustegevusest | -30.077 | -46.642 | -42.529 | -45.363 | -37.906 |
| Intressitulud (kulu), muud tulud, neto | -7.757 | -8.315 | -8.551 | -5.555 | -2.752 |
| Muud, neto | 0.02 | -0.09 | -0.011 | -0.002 | -0.007 |
| Netotulu enne makse | -37.814 | -55.047 | -51.091 | -50.92 | -40.665 |
| Netotulu pärast makse | -37.814 | -55.047 | -51.091 | -50.92 | -40.665 |
| Netotulu enne erikulusid | -37.814 | -55.047 | -51.091 | -50.92 | -40.665 |
| Netotulu | -37.814 | -55.047 | -51.091 | -50.92 | -40.665 |
| Arvestatav tulu, v a erikulud | -37.814 | -55.047 | -51.091 | -50.92 | -40.665 |
| Arvestatav tulu, koos erikuludega | -37.814 | -55.047 | -51.091 | -50.92 | -40.665 |
| Jaotamisele kuuluv netotulu | -37.814 | -55.047 | -51.091 | -50.92 | -40.665 |
| Keskmine jaotamisele kuuluv aktsia kohta | 42.3545 | 41.335 | 38.8203 | 38.272 | 38.037 |
| Jaotatav EPS, v a erakorralised kulud | -0.8928 | -1.33173 | -1.31609 | -1.33048 | -1.06909 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Jaotamisele kuuluv normaal-EPS | -0.8928 | -1.33173 | -1.31609 | -1.33048 | -1.06909 |
| Ootamatud kulutused (tulu) |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 160.512 | 186.526 | 291.368 | 255.601 | 0.902 |
| Raha ja lühiajalised investeeringud | 155.385 | 183.259 | 287.496 | 243.765 | 0.879 |
| Raha ja ekvivalendid | 155.385 | 183.259 | 287.496 | 243.765 | 0.879 |
| Prepaid Expenses | 5.127 | 3.267 | 3.872 | 11.836 | 0.023 |
| Total Assets | 164.81 | 189.431 | 295.111 | 257.178 | 0.902 |
| Other Long Term Assets, Total | 0.804 | 0.341 | 0.384 | 0.181 | 0 |
| Total Current Liabilities | 26.237 | 18.921 | 55.524 | 3.748 | 2.188 |
| Accounts Payable | 9.997 | 5.15 | 16.782 | 0.699 | 0.055 |
| Accrued Expenses | 16.24 | 13.771 | 31.389 | 2.636 | 0.183 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 1.95 |
| Other Current Liabilities, Total | 0.413 | 0 | |||
| Total Liabilities | 239.624 | 117.275 | 100.84 | 29.223 | 2.188 |
| Total Long Term Debt | 204.789 | 89.671 | 39.634 | 22.777 | 0 |
| Long Term Debt | 204.789 | 89.671 | 39.634 | 22.777 | 0 |
| Other Liabilities, Total | 8.598 | 8.683 | 5.682 | 2.698 | 0 |
| Total Equity | -74.814 | 72.156 | 194.271 | 227.955 | -1.286 |
| Common Stock | 0.003 | 0.003 | 0.003 | 0.002 | 0 |
| Additional Paid-In Capital | 652.276 | 601.523 | 579.755 | 484.372 | 0.002 |
| Retained Earnings (Accumulated Deficit) | -727.093 | -529.37 | -385.487 | -256.419 | -1.288 |
| Total Liabilities & Shareholders’ Equity | 164.81 | 189.431 | 295.111 | 257.178 | 0.902 |
| Total Common Shares Outstanding | 41.4689 | 30.5112 | 28.516 | 24.7283 | 25.8835 |
| Property/Plant/Equipment, Total - Net | 3.494 | 2.564 | 3.359 | 1.396 | |
| Property/Plant/Equipment, Total - Gross | 4.965 | 3.416 | 3.69 | 1.404 | |
| Accumulated Depreciation, Total | -1.471 | -0.852 | -0.331 | -0.008 | |
| Current Port. of LT Debt/Capital Leases | 0 | 7.353 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 139.843 | 160.512 | 197.813 | 209.257 | 145.741 |
| Raha ja lühiajalised investeeringud | 129.574 | 155.385 | 196.838 | 207.392 | 138.09 |
| Raha ja ekvivalendid | 129.574 | 155.385 | 196.838 | 207.392 | 138.09 |
| Prepaid Expenses | 10.269 | 5.127 | 0.975 | 1.865 | 7.651 |
| Total Assets | 144.01 | 164.81 | 201.931 | 213.502 | 149.049 |
| Property/Plant/Equipment, Total - Net | 3.363 | 3.494 | 3.313 | 3.44 | 2.503 |
| Property/Plant/Equipment, Total - Gross | 4.98 | 4.965 | 4.617 | 4.569 | 3.483 |
| Accumulated Depreciation, Total | -1.617 | -1.471 | -1.304 | -1.129 | -0.98 |
| Other Long Term Assets, Total | 0.804 | 0.804 | 0.805 | 0.805 | 0.805 |
| Total Current Liabilities | 14.443 | 26.237 | 22.879 | 21.075 | 11.394 |
| Accounts Payable | 4.805 | 9.997 | 7.135 | 5.758 | 2.858 |
| Accrued Expenses | 9.638 | 16.24 | 14.799 | 15.317 | 8.536 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.945 | 0 | 0 | ||
| Total Liabilities | 234.205 | 239.624 | 228.354 | 220.502 | 111.014 |
| Total Long Term Debt | 211.317 | 204.789 | 196.728 | 190.535 | 91.037 |
| Long Term Debt | 211.317 | 204.789 | 196.728 | 190.535 | 91.037 |
| Other Liabilities, Total | 8.445 | 8.598 | 8.747 | 8.892 | 8.583 |
| Total Equity | -90.195 | -74.814 | -26.423 | -7 | 38.035 |
| Common Stock | 0.004 | 0.003 | 0.003 | 0.003 | 0.003 |
| Additional Paid-In Capital | 674.708 | 652.276 | 645.62 | 613.952 | 608.067 |
| Retained Earnings (Accumulated Deficit) | -764.907 | -727.093 | -672.046 | -620.955 | -570.035 |
| Total Liabilities & Shareholders’ Equity | 144.01 | 164.81 | 201.931 | 213.502 | 149.049 |
| Total Common Shares Outstanding | 43.5711 | 41.4689 | 41.1438 | 38.3724 | 38.1498 |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netotulu/algväärtus | -197.723 | -143.883 | -129.068 | -255.131 | -1.288 |
| Raha majandustegevusest | -146.53 | -148.457 | -69.688 | -36.51 | -1.023 |
| Mittelikviidsed varad | 31.056 | 22.22 | 7.34 | 228.135 | 0.05 |
| Makstud intressid | 7.033 | 4.069 | 3.464 | 1.007 | 0 |
| Muutused tööjõus | 19.517 | -27.315 | 51.717 | -9.522 | 0.215 |
| Tulu investeeringutelt | -1.041 | -0.328 | -1.04 | -25.25 | 0 |
| Muud rahavood investeeringutelt, kokku | -25.118 | 0 | |||
| Rahavood investeeringutelt | 120.042 | 44.708 | 114.459 | 304.646 | 1.902 |
| Aktsiate emiteerimine (tagasiost), neto | 24.596 | 1.944 | 89.459 | 191.472 | 0.002 |
| Laenu väljastamine (kustutamine), neto | 95.446 | 42.764 | 25 | 113.174 | 1.9 |
| Rahaline kogumuutus | -27.529 | -104.077 | 43.731 | 242.886 | 0.879 |
| Raha majandustegevusest | 0.62 | 0.521 | 0.323 | 0.008 | |
| Kapitalikulutused | -1.041 | -0.328 | -1.04 | -0.132 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -37.814 | -197.723 | -142.676 | -91.585 | -40.665 |
| Cash From Operating Activities | -39.669 | -146.53 | -105.834 | -70.818 | -44.757 |
| Cash From Operating Activities | 0.146 | 0.62 | 0.452 | 0.277 | 0.128 |
| Non-Cash Items | 9.184 | 31.056 | 22.811 | 15.296 | 7.732 |
| Cash Interest Paid | 2.546 | 7.033 | 4.938 | 2.919 | 1.388 |
| Changes in Working Capital | -11.185 | 19.517 | 13.579 | 5.194 | -11.952 |
| Cash From Investing Activities | -0.214 | -1.041 | -0.629 | -0.495 | -0.067 |
| Capital Expenditures | -0.214 | -1.041 | -0.629 | -0.495 | -0.067 |
| Cash From Financing Activities | 14.072 | 120.042 | 120.042 | 95.446 | 0 |
| Issuance (Retirement) of Stock, Net | 14.072 | 24.596 | 24.596 | 0 | 0 |
| Issuance (Retirement) of Debt, Net | 95.446 | 95.446 | 95.446 | ||
| Net Change in Cash | -25.811 | -27.529 | 13.579 | 24.133 | -44.824 |
| Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
|---|---|---|---|---|---|---|
| Frazier Healthcare Partners | Venture Capital | 15.3707 | 8407153 | 1 | 2023-04-13 | LOW |
| Takeda Pharmaceutical Co Ltd | Corporation | 13.6377 | 7459286 | 0 | 2023-03-30 | LOW |
| The Carlyle Group | Private Equity | 5.3662 | 2935106 | 2935106 | 2023-03-31 | MED |
| Abingworth Management Limited | Venture Capital | 5.3662 | 2935106 | 1500000 | 2023-03-01 | LOW |
| Medicxi Ventures (UK) LLP | Venture Capital | 4.542 | 2484274 | 0 | 2023-03-31 | LOW |
| Invesco Advisers, Inc. | Investment Advisor | 3.7968 | 2076680 | -21533 | 2023-03-31 | LOW |
| Avidity Partners Management LP | Hedge Fund | 3.7454 | 2048600 | 148600 | 2023-03-31 | HIGH |
| Ensign Peak Advisors, Inc. | Foundation | 3.22 | 1761191 | 0 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.6458 | 1447159 | -26985 | 2023-03-31 | LOW |
| 683 Capital Management LLC | Hedge Fund | 2.4234 | 1325500 | -24500 | 2023-03-31 | MED |
| Socks (David A) | Individual Investor | 2.2154 | 1211756 | 0 | 2023-03-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.1492 | 1175532 | 100892 | 2023-03-31 | LOW |
| Newtyn Management, LLC | Hedge Fund | 1.2469 | 682027 | 197953 | 2023-03-31 | MED |
| Nabulsi (Azmi) | Individual Investor | 1.1592 | 634039 | 10000 | 2023-04-11 | LOW |
| GW&K Investment Management, LLC | Investment Advisor | 1.0949 | 598848 | 4691 | 2023-03-31 | LOW |
| Gilder Gagnon Howe & Co. LLC | Hedge Fund | 1.0126 | 553829 | 2002 | 2023-03-31 | |
| Opaleye Management Inc. | Hedge Fund | 0.9068 | 496000 | 78500 | 2023-03-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.8479 | 463743 | 12394 | 2023-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.8202 | 448611 | 13567 | 2023-03-31 | LOW |
| Medical Strategy GmbH | Investment Advisor | 0.7723 | 422425 | -71633 | 2023-01-31 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group530K+
Kauplejad
87K+
Igakuiste aktiivsete klientide arv
$46M+
Igakuine investeerimise maht
$31M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
Kauplemise vahendustasu
0
- 1:1
Finantsvõimendus
1:1
- 20
- 100
- 500
- 1000
- 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind
Close
Lühike Pikk
Phathom Pharmaceuticals, Inc. Company profile
Ettevõttest Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. on hilises kliinilises staadiumis biofarmatseutiline ettevõte, mis keskendub seedetrakti haiguste ravimeetodite väljatöötamisele ja turustamisele. Ettevõtte tootekandidaat vonoprasan on suukaudne väikesemolekulaarne kaaliumiga konkureeriv happeblokaator (P-CAB). P-CAB on ravimite klass, mis blokeerivad happesekretsiooni maos. Vonoprasan avaldab mõju ja on näidanud kliinilist kasu gastroösofageaalse reflukshaiguse (GERD) ravis ning kombinatsioonis antibiootikumidega Helicobacter pylori (H. pylori) infektsiooni raviks. GERD ja H. pylori infektsioon on happega seotud seedetrakti haigused ja mõjutavad miljoneid inimesi. GERD on haigus, mis tekib siis, kui happelise maosisu tagasivool põhjustab häirivaid sümptomeid ja/või tüsistusi. Umbes 30% GERD-patsientidest on erosiivne söögitorupõletik. H. pylori on bakteriaalne patogeen.
| Industry: | Biotechnology & Medical Research (NEC) |
100 Campus Drive,
Suite 102
07932
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 530,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com